Pharmaceutical stocks on the A-share market have been strengthening recently, with the innovation drug segment surging over 20% in the past month. The sustainability of this rally and future investment opportunities are drawing significant market attention. Pi Jinsong, fund manager of the Chuangjin Hexin Healthcare Stock Fund, believes the pharmaceutical sector is poised to become a key market theme, with industry opportunities concentrated in the innovation track. He highlights a bullish outlook on innovation drugs and CRO sub-sectors, while noting that innovation drugs currently offer clear allocation value, but investors must select stocks based on fundamentals.
Regarding the strong performance of the pharmaceutical sector, particularly the innovation drug segment's 20% monthly gain, Pi Jinsong attributes this to robust fundamentals. Key drivers include rapid earnings growth, continuous progress in clinical trials for listed companies, and significant data readouts for domestic innovation drugs at academic conferences like ASCO and ESMO. Some clinical studies show potential to change existing treatment standards, and domestic innovation drugs are accelerating integration into the global supply chain via licensing deals. The first-half performance of innovation drug stocks significantly deviated from fundamentals, so the recent rally is a correction of earlier overselling. Additionally, funds flowing out of elevated tech sectors are seeking growth assets, with innovation drugs being a rare direction offering strong earnings and a solid investment thesis.
On whether this pharmaceutical rally is a dead cat bounce or a reversal, Pi Jinsong suggests it is likely a reversal. Since last August, the pharmaceutical sector has been under continuous adjustment without significant fundamental headwinds, primarily due to market style favoring extreme growth, where popular sectors absorbed most market capital. To determine a reversal, two signals are crucial: first, a return to balanced market style, with mid-year reports showing healthcare holdings at a historic low of 3.95% among top-10 mutual fund positions; second, a broader sector rally driven by licensing deals for domestic innovation drugs in 2025. As licensing becomes routine, the market will focus more on deal quality, company operations, and clinical progress, with high-quality companies expected to reverse first.
Pi Jinsong confirms that innovation drugs currently have allocation value, but stock selection is essential. The market capitalization potential of innovation drug companies is tied to peak sales, with short-term catalysts from sales and clinical data. Currently, most companies' market caps only reflect domestic business potential, with little to no value assigned to overseas opportunities. As domestic companies have extensive pipelines, there remains room for market cap growth. From 2025 to 2032, multinational pharmaceutical companies face $370 billion in sales patent expirations, creating abundant collaboration opportunities for domestic innovation drugs. Domestic firms have promising molecules in areas like ADC, small nucleic acids, and TCE, with partnerships potentially delivering significant long-term value. On the policy front, this year's government work report for the first time designated biomedicine as a strategic emerging industry pillar, while domestic innovation drug sales remain low with large room for growth, ensuring high domestic growth certainty.
Pi Jinsong believes the pharmaceutical sector has the potential to become a main market theme, with structural opportunities centered on innovation. He favors innovation drugs and CRO. The innovation drug industry is in an upward cycle, transitioning from pure R&D investment to domestic and international commercialization. The trend of Chinese innovation drugs going global is just beginning, with high earnings growth, licensing deals, and clinical progress enhancing company value. Domestic-oriented CRO benefit from increased R&D investment in domestic innovation drugs, with safety evaluations and clinical orders recovering rapidly. Outward-oriented CRO are deeply integrated into the global innovation supply chain, handling commercial production for blockbuster drugs.
Pi Jinsong states that for the current and near future, the operational strategy focuses on innovation drugs, which are entering a resonance period driven by commercialization and clinical data. Domestic innovation drugs are growing rapidly overall, with continuous product launches extending the earnings cycle. From 2026, multiple domestic innovation drugs will begin sales in Europe and the US, offering significant profit elasticity. Many potential domestic innovation drugs are in critical clinical stages, and positive data could catalyze stock prices. Regarding risks, he highlights the need to monitor geopolitical risks impacting innovation drug investment sentiment and the risk of clinical data falling short of expectations.
Comments